Cargando…
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
BACKGROUND: Empagliflozin is a potent, selective sodium glucose cotransporter 2 (SGLT2) inhibitor in development as an oral antidiabetic treatment. This QT interval study assessed potential effects of empagliflozin on ventricular repolarisation and other electrocardiogram (ECG) parameters. METHODS:...
Autores principales: | Ring, Arne, Brand, Tobias, Macha, Sreeraj, Breithaupt-Groegler, Kerstin, Simons, Gudrun, Walter, Beate, Woerle, Hans J, Broedl, Uli C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648489/ https://www.ncbi.nlm.nih.gov/pubmed/23617452 http://dx.doi.org/10.1186/1475-2840-12-70 |
Ejemplares similares
-
Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects
por: Ring, Arne, et al.
Publicado: (2013) -
“Thorough QT/QTc in a Dish”: Can Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Predict Thorough QT Outcomes?
por: Vargas, Hugo M.
Publicado: (2019) -
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
por: Baron, Kyle T., et al.
Publicado: (2016) -
Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016) -
The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study
por: Palmisano, Maria, et al.
Publicado: (2016)